NV-NTT
13.5.2020 10:44:08 CEST | Business Wire | Press release
The city of Las Vegas and NTT Corporation (NTT) today announced the Accelerate Smart project has expanded to include two new locations – the city’s Community Healing Garden and a portion of Las Vegas Boulevard at South Main Street and East St. Louis Avenue. As part of the partnership, NTT and the city plan to further expand the smart cities project to Bob Baskin Park, Rotary Park, Stupak Park and Ethel Pearson Park this summer before adding six additional parks by the end of 2020.
Following the success of the initial pilot , which has improved traffic congestion and wrong way driving, NTT will expand the project to provide real-time alerts of safety conditions and maintenance issues to improve public safety and provide a better experience for citizens and visitors. The city’s Smart Park Initiative is designed to increase public safety, while providing awareness of activity to generate usage and operations benchmarks that allow leadership to make more informed decisions.
In total, high-definition optical and audio sensors will now be deployed at 14 locations across the city, which enable an automated system to notify law enforcement and maintenance personnel of safety hazards, such as large crowds, gunshots, breaking glass and vandalism.
“Cities that learn, understand and invest in technology will be the cities of the future, and Las Vegas is at the forefront of innovation,” said Michael Sherwood, Director of Innovation and Technology, city of Las Vegas. “Our Smart Cities pilot has been such a success that we are excited to expand the program to several new locations in the heart of our city, which will continue to improve the lives of our residents and visitors.”
The initial proof of concept provided information to city personnel to increase situational awareness and provide a foundation for traffic management. With the expansion of the smart cities project, Las Vegas will leverage a dashboard to access and view sensors, data streams and analytics. The timely alerts and predictions enable the city to monitor and review events and allow them to dispatch safety and maintenance personnel in a timely manner.
The NTT Accelerate Smart data platform is a secure, distributed platform that captures data via sensors and micro data centers in the designated areas through video and sound, while also integrating historical data sources such as crime, weather and social media. By leveraging cognitive analytics, including machine learning technologies, the system learns normal patterns and can detect and alert authorities of patterns that appear abnormal.
“As we accelerate our smart cities project in Las Vegas, it demonstrates how a more connected society directly benefits citizens,” said Bill Baver, Go to Market Leader, Smart World Team, NTT. “Cities like Las Vegas are capitalizing on successful pilots and beginning to imagine the benefits these technologies can have for their residents and visitors. However, smart is not confined to city limits, as it also extends to stadiums, shopping malls and manufacturing facilities by leveraging similar concepts that have been proven successful in Las Vegas.”
The Accelerate Smart solution deployed in Las Vegas is built on NTT’s innovative Cognitive Foundation™ architecture, which enables remote creation, management and operation of information and communications technology resources, from devices and networks to the cloud. It also incorporates hyperconverged infrastructure and IoT gateways, as well as virtualization software hosting predictive analytics applications.
The partnership with NTT is part of the city of Las Vegas’ charter in becoming a smart city to provide safe, reliable and efficient civic technology that stimulates economic growth. To learn more about the Smart Cities initiative in Las Vegas, visit NTT’s website and watch the case study on YouTube .
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005261/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom